Fortrea Holdings opened lower at $19.96, compared with its previous close of $20.38. In the last trading session, the stock traded between $18.97 and $20.29. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Fortrea Holdings is now worth
$ 54.45
Resulting in a loss of
$ 45.55 (45.55%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
63.64%
Hold
18.18%
Sell
18.18%
Markets Today
Today's Change
$-0.32 (-1.57%)
Day High
$20.29
Day Low
$18.97
Day Open
$19.96
Prev Close
$20.38
Volume
13,01,771
1W Return
-3.67%
1M Return
-4.52%
3M Return
2.78%
6M Return
33.82%
1Y Return
70.14%
Fundamentals
Market Cap ($ Mn)
1,936
PE Ratio
-
PB Ratio
3.41
PEG Ratio
-
ROE
-124.69%
ROCE
-43.39%
EPS (TTM)
$0.01
Investment Returns
1 Week
-3.67%
1 Month
-4.52%
3 Months
2.78%
6 Months
33.82%
9 Months
73.08%
Financials
Quarterly
All values in $ Mn
710.3
Jun 25
701.3
Sep 25
660.5
Dec 25
636.5
Mar 26
678.2
Jun 26
691.5
Sep 26
Updates
2Nov
TD Cowen raises Fortrea price target to $26, maintains Buy
TD Cowen raised Fortrea Holdings' price target from $23 to $26. The firm maintained a Buy rating on the stock. Analyst Charles Rhyee issued the updated rating and target.
10 days ago
20Oct
UBS maintains neutral on Fortrea Holdings, raises price target to $24
UBS maintains a Neutral rating on Fortrea Holdings. Price target raised from $22 to $24 by analyst Kevin Caliendo.
23 days ago
20Oct
Fortrea completes $45 million acquisition of Worldwide Clinical Trials unit
Fortrea completes acquisition of Worldwide Clinical Trials' Early Phase Services division for ~$45 million. Adds 200-bed CRU in San Antonio and 60,000 sq ft bioanalytical lab in Austin, Texas. Expands global early-phase capacity to over 570 beds. Enhances end-to-end platform by reducing operational handoffs between clinical and bioanalytical functions.
24 days ago
15Oct
Deutsche Bank upgrades Fortrea Holdings to Buy, raises price target to $25
Deutsche Bank upgraded Fortrea Holdings from Hold to Buy. Price target raised from $20 to $25 by analyst Justin Bowers. Upgrade signals improved confidence in the company's outlook.
28 days ago
11Sep
Fortrea grants RSUs, PSUs to five new hires under Nasdaq rule
Fortrea granted equity awards to five new employees on September 10, 2026. CFO Jason Knoblauch received 106,755 PSUs and 144,434 RSUs. Four other hires received a combined 157,500 RSUs. Awards vest over three years subject to employment and performance conditions. Grants approved under Nasdaq Listing Rule 5635(c)(4).
2mo ago
10Sep
Fortrea executives to speak at three September investor conferences
Fortrea executives to speak at Baird, Deutsche Bank, and RBC conferences. CEO Anshul Thakral and CFO Jason Knoblauch leading engagements. Baird fireside chat scheduled for September 15, 2026 at 2:00 pm EDT. Webcast and replay available on Fortrea’s Investor Relations site.
